热门资讯> 正文

Innate Pharma GAAP每股收益为-0.31欧元，收入为1，235万欧元

2024-09-12 13:15

Innate Pharma press release (NASDAQ:IPHA): 1H GAAP EPS of -€0.31.
Revenue of €12.35M (-69.3% Y/Y).
Cash position of €102.1 million as of June 30, 2024, anticipated cash runway to end of 2025.

More on Innate Pharma:

Innate falls on updated phase 1/2 data on blood cancer asset teamed with Sanofi
Seeking Alpha’s Quant Rating on Innate Pharma
Historical earnings data for Innate Pharma
Financial information for Innate Pharma
Historical earnings data for Innate Pharma S.A.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。